



Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference

02-23-2026 at 8:01 AM EST

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held in a virtual format February 25-26, 2026.

Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer and Keith Cummings, M.D., Chief Financial Officer, will participate in a fireside chat on Wednesday, February 25, 2026, at 2:40 p.m. Eastern Time.

Interested parties may access the live webcast of the fireside chat by visiting [here](#) or the [Investor Relations' Events & Presentation](#) page of Pliant's website. The webcast replay will be archived on the Pliant website for 30 days following the conclusion of the event.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. The Company's lead program is PLN-101095, a small molecule, dual-selective inhibitor of $\alpha_v\beta_3$ and $\alpha_v\beta_1$ integrins, that is being developed for the treatment of solid tumors. Pliant's early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: www.PliantRx.com. Follow us on social media [X](#), [LinkedIn](#) and [Facebook](#).

Investor and Media Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com